Vineti Announces New Board of Directors Member
by Amy DuRoss | January 15, 2020
Company announces the appointment of John Kontor, M.D.
SAN FRANCISCO, January 15, 2020 -- Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the appointment of John Kontor, M.D. to the company’s Board of Directors. Dr. Kontor, a clinical leader with deep experience in both patient care and medical technology, joins Vineti’s board as a new independent board member.
Dr. Kontor serves as Senior Vice President at Optum, where he leads Provider Technology Services, a technology-enabled services division that helps improve clinical and financial performance for provider organizations and their payer and life science partners. Dr. Kontor plays a pivotal role in leading Electronic Health Record (EHR) implementation, EHR optimization, population health/value-based operations efforts, and IT strategy.
Dr. Kontor’s unique perspective -- deeply valuable in the interconnected ecosystem of advanced therapies served by Vineti -- comes from his experience serving in multiple integrated delivery network (IDN) executive roles. Dr. Kontor has an extensive background in optimization of workflows, technology, and clinical content to drive clinical transformation across large health systems and organizations.
Prior to beginning his consulting career, Dr. Kontor practiced internal medicine for 14 years, focusing on ambulatory chronic disease management and inpatient critical care. Dr. Kontor received his Doctor of Medicine from the University of Florida in Gainesville and his Bachelor of Arts in Health Policy from Boston University.
“I look forward to bringing my knowledge of medical and provider technologies to the growing world of advanced therapies,” said Dr. Kontor. “Vineti already supports many of the industry leaders and top medical centers, and the need for technology like Vineti’s is expanding rapidly. I’m excited to help use digital technology to connect CAR-T therapies and other advanced therapeutics into mainstream medical practice.”
The Vineti software platform is specifically built to manage transformative new personalized therapies, such as CAR-T cell therapies, at scale while safeguarding patient safety and regulatory compliance. Vineti’s configurable, modular enterprise software platform improves cell and gene therapy manufacturing efficiency, makes these new therapies simpler for doctors and nurses to manage, enables regulatory compliance, and provides unprecedented control of the most complex supply chain in the history of medicine. The Vineti platform also enables seamless integrations with other technology systems and stakeholders in the personalized therapy ecosystem. Vineti is currently serving patients, healthcare providers, and researchers in hundreds of leading medical centers and manufacturing centers worldwide, on behalf of a growing number of biopharmaceutical partners.
“We are thrilled to welcome Dr. Kontor to our Board of Directors,” said Amy DuRoss, CEO and Co-Founder of Vineti. “His extensive experience in empowering medicine with new digital technology -- and his experience serving patients -- will be invaluable as Vineti continues to support the standardization and industrialization of these transformative therapies.”
In joining Vineti’s board, Dr. Kontor will expand a top-tier Directors team that includes leadership from Canaan, GE Ventures, J&J Innovation, Medidata, and Section 32. More information can be found here.
Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges that patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The Vineti software solution aligns and orchestrates the cell and gene therapy process and improves product performance overall for both clinical- and commercial-phase therapies. The Vineti platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. The platform can also be harnessed for drug products requiring companion diagnostics or REMS programs. The company is expanding rapidly, and the Vineti platform will be in use in hundreds of leading medical centers world-wide in 2020, on behalf of multiple biopharmaceutical partners. In 2019, the World Economic Forum honored Vineti as a World Economic Forum Technology Pioneer. Vineti is headquartered in San Francisco, California, with offices in Bethesda, Maryland and Yerevan, Armenia. For more information, please visit http://vineti.com.